Party Branch Secretary of the First Department of Hepatobiliary and Pancreatic Surgery, Associate Chief Physician. Graduated from Peking University Health Science Center with a Doctorate in Oncology. During the period of study and work, completed the multi-year rotation plan of the standardized residency training at Peking University, laying a solid foundation for the specialty of hepatobiliary and pancreatic tumor surgery. Served successively as Resident, Chief Resident, Attending Physician, and Associate Chief Physician, currently primarily engaged in the surgical specialty of hepatobiliary and pancreatic tumors. Has been working on the clinical frontline for a long time, participating in numerous complex surgeries such as hepatectomy, pancreaticoduodenectomy, distal pancreatectomy with splenectomy, and radical cholecystectomy for gallbladder cancer, cumulatively participating in and completing nearly a thousand surgeries, accumulating certain experience in surgical procedures and perioperative management within this specialty. Currently primarily engaged in clinical and basic research in the fields of colorectal liver metastases and primary liver cancer. Served as the principal investigator for a research project funded by the Wu Jieping Medical Foundation, and as the first participant in a project funded by the Ministry of Science and Technology and a project funded by the National Natural Science Foundation of China. Additionally, served as a sub-investigator in multiple clinical research projects, covering drug therapy for advanced primary liver cancer, conversion therapy for locally advanced liver cancer, postoperative adjuvant therapy for primary liver cancer, and drug therapy for advanced biliary tract cancer. Has published a total of 10 SCI papers and Chinese core journal papers, and serves as a reviewer for journals including *Hepatology International*, *Clinical and Translational Oncology*, and *Frontiers in Oncology*. Social Affiliations: Secretary-General, Hepatobiliary and Pancreatic Tumor Division, Beijing Cancer Prevention and Treatment Society; Member, CSCO Biliary Tract Professional Committee; Member, Tumor Gastroenterology Professional Committee, Chinese Anti-Cancer Association; Member, Hepatobiliary Surgery Professional Group, Integrated Traditional Chinese and Western Medicine Committee, Chinese Volunteer Association. Representative Achievements: (1) L. Wang, Q. Bao, K. Wang, Z. Li and B. Xing, Predictive Factors for Chemotherapy Response in Colorectal Liver Metastasis: A Retrospective Study Utilizing Next-Generation Sequencing, *Ann Surg Oncol*. 2025 Aug;32(8):6067-6079. (2) L. Wang, Q. Bao, K. Wang, Z. Li and B. Xing, ASO Author Reflections: Toward Precision Chemotherapy in Colorectal Liver Metastases: Integrating Genomics into Predictive Modeling, *Ann Surg Oncol*. 2025 Aug;32(8):6102-6103. (3) L. Wang, H. Wang, Y. Cui, M. Liu, K. Jin, D. Xu, K. Wang and B. Xing, Sintilimab plus lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: a phase 2 study, *FRONT ONCOL* 13 (2023), no. 1115109. (4) L. Wang, X. Yan, J. Li, K. Wang and B. Xing, Indocyanine green clearance test for the preoperative assessment of chemotherapy-related hepatic injury in patients with colorectal liver metastasis, *CANCER MANAG RES* 12 (2020), 3237-3245. (5) L. Wang, H. Wang, K. Jin, J. Li and B. Xing, Comparison of sequential, delayed and simultaneous resection strategies for synchronous colorectal liver metastases, *BMC SURG* 20 (2020), no. 161.